In 2018, WHO published interim guidelines recommending dolutegravir (DTG)-containing regimens as the preferred first- and second-line antiretroviral therapy (ART) regimens for people living with HIV.

The 2019 updated guidelines provide the latest recommendations based on rapidly evolving evidence of safety and efficacy and programmatic experience using DTG and EFV 400 mg in pregnant women and people coinfected with TB.